Literature DB >> 1313689

Insulin-like growth factors and cancer.

V M Macaulay1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1313689      PMCID： PMC1977607          DOI： 10.1038/bjc.1992.65

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  137 in total

1.  Functional receptors for insulin-like growth factors I and II in rat thymocytes and mouse thymoma cells.

Authors:  S Verland; S Gammeltoft
Journal:  Mol Cell Endocrinol       Date:  1989-12       Impact factor: 4.102

2.  Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates.

Authors:  H P Guler; J Zapf; C Schmid; E R Froesch
Journal:  Acta Endocrinol (Copenh)       Date:  1989-12

3.  Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor.

Authors:  C L Arteaga; C K Osborne
Journal:  Cancer Res       Date:  1989-11-15       Impact factor: 12.701

Review 4.  Signal transmission by the insulin-like growth factors.

Authors:  M P Czech
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

5.  Insulin-like growth factor II and the riddle of tumor-induced hypoglycemia.

Authors:  L Axelrod; D Ron
Journal:  N Engl J Med       Date:  1988-12-01       Impact factor: 91.245

6.  Insulin-like growth factor I receptors in normal and neoplastic human endometrium.

Authors:  F Talavera; R K Reynolds; J A Roberts; K M Menon
Journal:  Cancer Res       Date:  1990-05-15       Impact factor: 12.701

7.  Antibody to type I insulinlike growth factor receptor inhibits growth of Wilms' tumor in culture and in athymic mice.

Authors:  T Gansler; R Furlanetto; T S Gramling; K A Robinson; N Blocker; M G Buse; D A Sens; A J Garvin
Journal:  Am J Pathol       Date:  1989-12       Impact factor: 4.307

8.  Human teratocarcinoma cells express functional insulin-like growth factor I receptors.

Authors:  S M Weima; L H Stet; M A van Rooijen; S C van Buul-Offers; E J van Zoelen; S W de Laat; C L Mummery
Journal:  Exp Cell Res       Date:  1989-10       Impact factor: 3.905

9.  Expression of two insulin-like growth factor-binding proteins in a human endometrial cancer cell line: structural, immunological, and genetic characterization.

Authors:  G Lamson; Y Oh; H Pham; L C Giudice; R G Rosenfeld
Journal:  J Clin Endocrinol Metab       Date:  1989-10       Impact factor: 5.958

10.  Production of immunoreactive insulin-like growth factor I and response to exogenous IGF-I in small cell lung cancer cell lines.

Authors:  G Jaques; M Rotsch; C Wegmann; U Worsch; M Maasberg; K Havemann
Journal:  Exp Cell Res       Date:  1988-06       Impact factor: 3.905
View more
  96 in total

1.  Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation.

Authors:  H Yu; J Mistry; M J Nicar; M J Khosravi; A Diamandis; J van Doorn; A Juul
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

2.  Expression of insulin like growth factor II and its receptor in hepatocellular carcinogenesis.

Authors:  Z R Fan; D H Yang; J Cui; H R Qin; C C Huang
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

3.  Plasma levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in women with cervical neoplasia.

Authors:  Si Won Lee; Soo Yoon Lee; Sa Ra Lee; Woong Ju; Seung Cheol Kim
Journal:  J Gynecol Oncol       Date:  2010-09-28       Impact factor: 4.401

4.  Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies.

Authors:  S C Larsson; A Wolk
Journal:  Diabetologia       Date:  2011-01-28       Impact factor: 10.122

5.  IGF-I stimulates proliferation of spontaneously immortalized human keratinocytes (HACAT) by autocrine/paracrine mechanisms.

Authors:  G Pozzi; M Guidi; F Laudicina; M Marazzi; L Falcone; R Betti; C Crosti; E E Müller; G E DiMattia; V Locatelli; A Torsello
Journal:  J Endocrinol Invest       Date:  2004-02       Impact factor: 4.256

6.  Apicidin-resistant HA22T hepatocellular carcinoma cells massively promote pro-survival capability via IGF-IR/PI3K/Akt signaling pathway activation.

Authors:  Hsi-Hsien Hsu; Li-Hao Cheng; Tsung-Jung Ho; Wei-Wen Kuo; Yueh-Min Lin; Ming-Cheng Chen; Nien-Hung Lee; Fuu-Jen Tsai; Kun-Hsi Tsai; Chih-Yang Huang
Journal:  Tumour Biol       Date:  2013-08-30

7.  Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequences.

Authors:  Doron Amit; Sagi Tamir; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2013-01-26

8.  Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early- and late-stage breast cancer: mutual relationship and possible correlations with patients' hormonal status.

Authors:  R E Favoni; A de Cupis; A Perrotta; S Sforzini; D Amoroso; F Pensa; L Miglietta
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

9.  Race/ethnic variation in serum levels of IGF-I and IGFBP-3 in US adults.

Authors:  David Berrigan; Nancy Potischman; Kevin W Dodd; Stephen D Hursting; Jackie Lavigne; J Carl Barrett; Rachel Ballard-Barbash
Journal:  Growth Horm IGF Res       Date:  2008-09-21       Impact factor: 2.372

Review 10.  Nutrition, hormones, and breast cancer: is insulin the missing link?

Authors:  R Kaaks
Journal:  Cancer Causes Control       Date:  1996-11       Impact factor: 2.506
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.